Head of External Affairs
Jack Hirschfield joined NRx in May 2021 and leads External Affairs for NRx. Prior to joining NRx, Jack was an award-winning broadcast journalist, focusing on politics and healthcare. Jack also served as Director of Communications for Congressman Michael McCaul (TX-10) where he ran media and communication efforts for the Congressman across the globe. Jack began his healthcare career at Pfizer, serving as Director of Public Affairs and Director of Corporate Affairs. Jack served in a similar position leading U.S. Brand Communications for Oncology and Neurology at AbbVie, where he was responsible for the communications surrounding multiple launches and managing several campaigns. Jack holds a Bachelor of Arts degree from the University of Iowa.
Chief Business Officer
Randy brings more than 30 years of investment banking experience dedicated to advising biopharmaceutical companies worldwide. He has advised on numerous corporate M&A, partnering transactions and public and private financings. Most recently, Randy was a Managing Director at Young & Partners, a boutique investment banking firm serving the life sciences and chemical industries. Prior to Young & Partners, Randy was Head of Health Care Investment Banking for the Americas at Dresdner Kleinwort Wasserstein and worked for more than 15 years at Lehman Brothers as Managing Director in the Healthcare Group, Managing Director in the Mergers and Acquisitions Group and as Co-Head of Healthcare Mergers & Acquisitions. Randy received an AB degree in Economics at Harvard College and earned an MBA from Harvard Business School.
Chief Strategy Officer & Senior Scientist
Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology, four master’s degrees, and an additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely and was elected by faculty in 1999 to full professor. Dr. McBride has served at multiple universities in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as an adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.
Chief Financial Officer
Mr. Fricker has more than 30 years of pharmaceutical and biotechnology finance experience including leadership roles in financial reporting, financial planning and analysis, treasury, and tax policy. Prior to joining NRx he was Vice President of Finance and Chief Accounting Officer for Immunomedics, Inc. and was instrumental in preparing the Company for commercialization and its eventual sale to Gilead. During his career, Mr. Fricker has been responsible for building out finance organizations for both Fortune 100 companies as well as pre-commercial biotech companies. He has held leadership roles at J.M. Huber Corporation, Tyco International, Johnson & Johnson, and Bristol-Meyers Squibb. He is a Certified Public Accountant and holds a B.S. in Accounting from The Pennsylvania State University, together with an MBA from Villanova University.
Dr. Lavin is a highly respected biostatistician with more than 30 years experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health, and a member of the Department of Surgery at Harvard Medical School where he was affiliated for more than 25 years. He co-founded Boston Biostatistics in 1983, a company known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 US Food and Drug Administration (FDA) approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years advising the FDA on complex statistical and policy issues.
General Counsel & Secretary
Mrs. Daigneault joined NRx as its Corporate Secretary in September 2020. Prior to joining NRx, she was co-founder and Chief Operating Officer of Quantum Governance LLC, where she continues to serve as a director. She also served as Vice President and Chief Legal Counsel for Teligent, Inc. and its successor companies, First Avenue Networks and FiberTower Corporation, all publicly traded telecommunications companies, from October 2000 to May 2008. Ms. Daigneault began her legal career with Milbank LLP and was a Partner at the Washington, D.C. law firm of Tucker, Flyer & Lewis (now Venable LLP) where she represented clients on various corporate and commercial transactions. Ms. Daigneault holds a Bachelor of Science, Magna Cum Laude, from Georgetown University and a Juris Doctor from Georgetown University Law Center.
Head of Operations & Chief Commercial Officer
Mr. Besthof is a global biopharmaceutical executive with a 25+ year career leading global pipeline & country operational marketing & sales roles. He has managed numerous specialty disease area, from small to billion-dollar brands in Ophthalmology, Neuroscience, Pain, and Pulmonary Vascular Disease. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President of Commercial Development for Neuroscience & Pain. Earlier in his career Mr. Besthof worked for Deutsche Bank and for various consulting firms. He holds a B.A. from Case Western Reserve University and a Master’s Degree in International Management from the Thunderbird School of Global Management.
Chairman and Chief Executive Officer
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.